ResusX:Podcast Is high-flow nasal oxygen as effective as non-invasive ventilation in acute cardiogenic pulmonary Edema?
When a patient crashes with acute cardiogenic pulmonary edema, emergency teams need fast, effective solutions. For years, non-invasive ventilation (NIV) has been the gold standard — but could high-flow nasal cannula (HFNC) be just as good?
In this episode, we break down a prospective, randomized trial published in the American Journal of Emergency Medicine (Dec 2025) that compared HFNC head-to-head with NIV in the ED. The results? No difference in survival, respiratory rates, or dyspnea scores between the two therapies.
We’ll explore:
-
Why HFNC may rival NIV for managing ACPE
-
The surprising equivalence in clinical outcomes at 30, 60, and 120 minutes
-
Patient comfort and tolerability — where HFNC may hold the edge
-
What this means for ED practice, protocols, and future airway management
If you’re an emergency physician, intensivist, or resuscitationist, this study has big implications: it suggests you may have more flexibility — and your patients, more comfort — than ever before.